Informations générales (source: ClinicalTrials.gov)
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy
Interventional
Phase 3
Annexon, Inc. (Voir sur ClinicalTrials)
juillet 2024
juillet 2027
05 mai 2026
The primary purpose of the study is to determine if IVT injections of vonaprument every
month reduce vision loss in participants with dry AMD with GA.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Eric SOUIED | 28/08/2025 14:50:04 | Contacter | ||
Critères
Tous
- Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the
independent Central Reading Center.
Exclusion Criteria:
- Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod
dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil
maculopathy) in either eye.
NOTE: Other protocol-defined inclusion and exclusion criteria apply.